Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.40 |
| ▸ | RORA | P35398 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | RORB | Q92753 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6698507 | 0.96 | PGR (0.40) | PGRRORARORCRORBKDM4E | |
| SCHEMBL5231048 | 0.94 | TSHR (0.36) | KDM4EHSD17B10PLA2G2AMTNR1ADPP4 | |
| SCHEMBL5231638 | 0.92 | TSHR (0.37) | KDM4EHSD17B10PLA2G2AMTNR1ADPP4 | |
| SCHEMBL5231951 | 0.92 | POLB (0.34) | KDM4EHSD17B10MAPTDPP4TP53 | |
| SCHEMBL5232653 | 0.92 | MAPT (0.36) | KDM4EHSD17B10MAPTPLA2G2AAVPR1B | |
| SCHEMBL5235811 | 0.91 | TP53 (0.35) | RORCKDM4EHSD17B10MAPTDPP4 | |
| SCHEMBL5275959 | 0.90 | RORA (0.37) | PGRRORARORCRORBKDM4E | |
| SCHEMBL5233701 | 0.90 | TSHR (0.36) | KDM4EHSD17B10PLA2G2AMTNR1ADPP4 | |
| SCHEMBL5230679 | 0.89 | DPP4 (0.36) | KDM4EHSD17B10MAPK8MAPTDPP4 | |
| SCHEMBL5237350 | 0.89 | RORA (0.37) | RORARORCRORBKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | PGR 4067/4885RORA 2682/4885RORC 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.